Competitive Advantages:
Efficient and sustained drug delivery system, Decreases frequency of injections to treat ocular diseases, Adaptable for different treatment methods.
The present invention concerns nanoparticles useful for treating posterior segment ocular diseases or conditions, such as macular degeneration and diabetic retinopathy; compositions comprising the nanoparticles; methods for producing the nanoparticles; and methods for treating posterior segment ocular diseases or conditions, comprising administering the nanoparticles or compositions to the ocular posterior segment of an afflicted eye.Current treatment methods for Age-related macular degeneration (AMD) require frequent and unpleasant ocular injections. Additionally, therapeutic interventions for posterior segment ocular diseases are limited due to the physiological barriers of the eye. The nanoparticle-based dual-drug delivery system is the solution for sustained drug release. This formulation contains the anti-HIF agent Digoxin (DIG) and the corticosteroid Triamcinolone Acetonide (TA), a VEGF suppressor, to treat AMD as well as related posterior segment ocular diseases. The method of drug release is adjusted by nanoparticle composition, concentration of drug, and porous properties. Through this nanoparticle system, the frequency of injections is decreased to improve patient comfort and compliance.
Brochure
